Search Results

Cybrexa Therapeutics announced the Company will regain all rights to CBX-12, a clinical-stage, first-in-class peptide drug conjugate that utilizes Cybrexa’s proprietary alphalex technology to enhance delivery of exatecan to tumor cells, as its collaboration partner, Exelixis, Inc., has provided a notice of termination for the right to acquire CBX-12.

Cybrexa Therapeutics today announced that John Maraganore, Ph.D., has joined as a Strategic Advisor to the Company’s Executive Leadership Team.

Cybrexa Therapeutics today announced it will present data findings on its preclinical candidate, CBX-15 (alphalex™-MMAE) for the treatment of triple negative breast cancer in a poster session at the 35th AACR-NCI-EORTC (ANE) Symposium.

Cybrexa Therapeutics announced that new data for its lead compound, CBX-12, a first-in-class investigational PDC, will be presented at the 2023 American Society of Clinical Oncology Annual Meeting being held in Chicago on June 2-6.

Cybrexa Therapeutics today announced the appointment of Michael N. Needle, MD as Chief Medical Officer.

Cybrexa Therapeutics announced the appointments of Laurie Kenvin as Vice President of Clinical Operations and Nick Saccomano, Ph.D., to the Company’s Scientific Advisory Board.

Exelixis, Inc. and Cybrexa Therapeutics announced that the companies have entered into an exclusive collaboration agreement providing Exelixis the right to acquire CBX-12, a clinical-stage, first-in-class peptide-drug conjugate that utilizes Cybrexa’s proprietary alphalex technology to enhance delivery of exatecan to tumor cells.